Completed PHASE1 INTERVENTIONAL NCT00357292

Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers

Comparison of the Ocular Tolerance, the Safety and the Ocular Pharmacokinetics After One Drop of Three Different Concentrations of T1225 (0.5% - 1.0% - 1.5%) in 48 Healthy Volunteers

Sponsor: Laboratoires Thea

Conditions Eye Infections, Bacterial

Interventions Azithromycin (T1225)

Updated 5 times since 2017 Last updated: Jul 26, 2006 Started: Mar 31, 2002 Completion: Apr 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Eye Infections, Bacterial, this trial is completed. The trial is conducted by Laboratoires Thea and has accumulated 5 data snapshots since 2002. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Mar 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Laboratoires Thea

Data source: Laboratoires Thea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.